September 18, 2025

Benitec Biopharma Inc. (BNTC) Investor Outlook: Analyzing the 81% Potential Upside in Biotechnology

Benitec Biopharma Inc. (NASDAQ: BNTC) has been making waves in the biotechnology sector with its promising pipeline of novel genetic medicines. This clinical-stage company, headquartered in Hayward, California, is focused..

Alumis Inc. (ALMS) Stock Analysis: A Biotech with a Potential 360% Upside

Alumis Inc. (NASDAQ: ALMS), a burgeoning name in the biotechnology sector, is attracting significant attention from investors, primarily due to its promising pipeline in autoimmune disorders and a staggering potential..

Tvardi Therapeutics, Inc. (TVRD) Stock Analysis: A Biotech with a 46% Upside Potential

Tvardi Therapeutics, Inc. (TVRD), a promising entity in the biotechnology sector, is capturing the interest of investors with its focus on developing innovative therapies targeting STAT3 to address fibrosis-driven diseases...

CytomX Therapeutics, Inc. (CTMX) Stock Analysis: Exploring a Potential 197.93% Upside in Biotechnology

CytomX Therapeutics, Inc. (NASDAQ: CTMX) is drawing attention from investors with an impressive potential upside of nearly 198%, as suggested by its average target price of $5.75. This California-based biopharmaceutical..

Viemed Healthcare, Inc. (VMD) Stock Analysis: A Potential 99% Upside in the Medical Device Sector

Viemed Healthcare, Inc. (VMD), a key player in the medical devices sector, presents a compelling investment opportunity with a remarkable potential upside of 99.39%. This Louisiana-based company, with a market..

Gossamer Bio, Inc. (GOSS) Stock Analysis: Exploring a Potential 196% Upside in the Biotech Sector

Gossamer Bio, Inc. (NASDAQ: GOSS) is making waves in the biotechnology industry with a staggering potential upside of 196.23%, according to recent analyst ratings. As a clinical-stage biopharmaceutical company, Gossamer..

Cartesian Therapeutics, Inc. (RNAC) Stock Report: Unpacking a 298% Potential Upside in Biotechnology

Investors with an appetite for innovation in the healthcare sector might find Cartesian Therapeutics, Inc. (RNAC) an intriguing prospect. The clinical-stage biotechnology company, headquartered in Frederick, Maryland, is pioneering mRNA..

Cytek Biosciences, Inc. (CTKB) Stock Analysis: Unpacking a 30.74% Potential Upside for Investors

Investors with an interest in the healthcare sector, specifically within the medical devices industry, may find Cytek Biosciences, Inc. (NASDAQ: CTKB) an intriguing opportunity. This Fremont, California-based company is renowned..

Cidara Therapeutics (CDTX) Stock Analysis: Exploring a 23% Potential Upside in the Biotech Arena

For investors with an eye on the biotechnology sector, Cidara Therapeutics, Inc. (NASDAQ: CDTX) presents an intriguing opportunity. Specializing in targeted therapies for critical diseases such as cancer and invasive..

Chevron Corporation (CVX) Investor Outlook: Analyzing a 4.27% Dividend Yield Amidst Market Dynamics

Chevron Corporation (NYSE: CVX) stands tall in the energy sector as one of the world’s leading oil and gas integrated companies. With a robust market capitalization of $322.55 billion, Chevron..

aTyr Pharma, Inc. (ATYR) Stock Analysis: Navigating a Potential 393.90% Upside in Biotech

Investors with an appetite for high-risk, high-reward opportunities may want to turn their attention to aTyr Pharma, Inc. (NASDAQ: ATYR), a biotechnology company poised at the cutting edge of fibrosis..

Real Estate Credit Investments maintains quarterly 3p dividend for 8 years (LON:RECI)

Real Estate Credit Investments has declared a first interim dividend of 3.0 pence per Ordinary Share for the year ending 31 March 2026, payable on 17 October 2025 to shareholders..

Abeona Therapeutics Inc. (ABEO) Stock Analysis: Eyeing a 263% Upside with Biotech Innovations

Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical-stage biopharmaceutical company, has captured the attention of investors with a compelling narrative of innovation in the healthcare sector. Specializing in gene and cell..

Aurora Cannabis Inc. (ACB) Stock Analysis: Exploring a 26.99% Upside Potential Amidst Revenue Growth

Aurora Cannabis Inc. (NASDAQ: ACB), a prominent player in the healthcare sector within the specialty and generic drug manufacturing industry, offers intriguing prospects for individual investors keen on the burgeoning..

Aura Biosciences, Inc. (AURA) Stock Analysis: Eyeing a 247.54% Potential Upside with Innovative Oncology Solutions

Aura Biosciences, Inc. (NASDAQ: AURA) is capturing the attention of investors with its promise of significant upside potential. With a 247.54% potential upside based on analyst ratings, this Boston-based biotechnology..

Candel Therapeutics, Inc. (CADL) Stock Analysis: Exploring a 306% Potential Upside in the Biotechnology Sector

In the dynamic world of biotechnology, Candel Therapeutics, Inc. (NASDAQ: CADL) is capturing investor attention with its promising potential upside of 306.34% as per analyst ratings. As a clinical stage..

ClearPoint Neuro Inc. (CLPT) Stock Analysis: Exploring a 172% Potential Upside in the Medical Devices Sector

ClearPoint Neuro Inc. (NASDAQ: CLPT) is a compelling player in the healthcare sector, specifically within the medical devices industry. Operating primarily in the United States, ClearPoint Neuro is making waves..

Spok Holdings, Inc. (SPOK) Stock Analysis: A 20% Upside Potential with Strong Dividend Yield

Spok Holdings, Inc. (NASDAQ: SPOK), a key player in the healthcare communication solutions sector, offers an intriguing investment opportunity with its current market dynamics. With a market capitalization of $359.72..

UroGen Pharma Ltd. (URGN) Stock Analysis: Navigating an 86% Potential Upside in the Biotech Sector

UroGen Pharma Ltd. (NASDAQ: URGN), a prominent player in the biotechnology industry, has recently captured investor attention with its substantial potential upside and promising pipeline of cancer treatment solutions. As..

Olema Pharmaceuticals (OLMA) Investor Outlook: Exploring a 222% Potential Upside

Olema Pharmaceuticals, Inc. (NASDAQ: OLMA), a trailblazing entity in the biotechnology sector, is gaining significant attention within the investment community for its promising pipeline and impressive potential upside. As a..

Search

Funds

September 18, 2025

Real Estate Credit Investments maintains quarterly 3p dividend for 8 years (LON:RECI)

Real Estate Credit Investments has declared a first interim dividend of 3.0 pence per Ordinary Share for the year ending 31 March 2026, payable on 17 October 2025 to shareholders on the register as of 26 September 2025...
Search

Funds

September 18, 2025

FTSE 100

Funds